Systemic hypothermia to prevent radiocontrast nephropathy (from the COOL-RCN randomized trial)

Gregg W. Stone, Kishor Vora, John Schindler, Claro Diaz, Tift Mann, George Dangas, Patricia Best, Donald E. Cutlip

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Radiocontrast nephropathy (RCN) develops in a substantial proportion of patients with chronic kidney disease (CKD) after invasive cardiology procedures and is strongly associated with subsequent mortality and adverse outcomes. We sought to determine whether systemic hypothermia is effective in preventing RCN in patients with CKD. Patients at risk for RCN (baseline estimated creatinine clearance 20 to 50 ml/min) undergoing cardiac catheterization with iodinated contrast ≥50 ml were randomized 1:1 to hydration (control arm) versus hydration plus establishment of systemic hypothermia (33°C to 34°C) before first contrast injection and for 3 hours after the procedure. Serum creatinine levels at baseline, 24 hours, 48 hours, and 72 to 96 hours were measured at a central core laboratory. The primary efficacy end point was development of RCN, defined as an increase in serum creatinine by ≥25% from baseline. The primary safety end point was 30-day composite rate of adverse events consisting of death, myocardial infarction, dialysis, ventricular fibrillation, venous complication requiring surgery, major bleeding requiring transfusion ≥2 U, or rehospitalization. In total 128 evaluable patients (mean creatinine clearance 36.6 ml/min) were prospectively randomized at 25 medical centers. RCN developed in 18.6% of normothermic patients and in 22.4% of hypothermic patients (odds ratio 1.27, 95% confidence interval 0.53 to 3.00, p = 0.59). The primary 30-day safety end point occurred in 37.1% versus 37.9% of normothermic and hypothermic patients, respectively (odds ratio 0.97, 95% confidence interval 0.47 to 1.98, p = 0.93). In conclusion, in patients with CKD undergoing invasive cardiology procedures, systemic hypothermia is safe but is unlikely to prevent RCN.

Original languageEnglish (US)
Pages (from-to)741-746
Number of pages6
JournalAmerican Journal of Cardiology
Volume108
Issue number5
DOIs
StatePublished - Sep 1 2011

Fingerprint

Hypothermia
Creatinine
Chronic Renal Insufficiency
Cardiology
Odds Ratio
Confidence Intervals
Safety
Ventricular Fibrillation
Cardiac Catheterization
Serum
Dialysis
Myocardial Infarction
Hemorrhage
Injections
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Stone, G. W., Vora, K., Schindler, J., Diaz, C., Mann, T., Dangas, G., ... Cutlip, D. E. (2011). Systemic hypothermia to prevent radiocontrast nephropathy (from the COOL-RCN randomized trial). American Journal of Cardiology, 108(5), 741-746. https://doi.org/10.1016/j.amjcard.2011.04.026

Systemic hypothermia to prevent radiocontrast nephropathy (from the COOL-RCN randomized trial). / Stone, Gregg W.; Vora, Kishor; Schindler, John; Diaz, Claro; Mann, Tift; Dangas, George; Best, Patricia; Cutlip, Donald E.

In: American Journal of Cardiology, Vol. 108, No. 5, 01.09.2011, p. 741-746.

Research output: Contribution to journalArticle

Stone, Gregg W. ; Vora, Kishor ; Schindler, John ; Diaz, Claro ; Mann, Tift ; Dangas, George ; Best, Patricia ; Cutlip, Donald E. / Systemic hypothermia to prevent radiocontrast nephropathy (from the COOL-RCN randomized trial). In: American Journal of Cardiology. 2011 ; Vol. 108, No. 5. pp. 741-746.
@article{da117b66ef6d4d1386dc822f07540936,
title = "Systemic hypothermia to prevent radiocontrast nephropathy (from the COOL-RCN randomized trial)",
abstract = "Radiocontrast nephropathy (RCN) develops in a substantial proportion of patients with chronic kidney disease (CKD) after invasive cardiology procedures and is strongly associated with subsequent mortality and adverse outcomes. We sought to determine whether systemic hypothermia is effective in preventing RCN in patients with CKD. Patients at risk for RCN (baseline estimated creatinine clearance 20 to 50 ml/min) undergoing cardiac catheterization with iodinated contrast ≥50 ml were randomized 1:1 to hydration (control arm) versus hydration plus establishment of systemic hypothermia (33°C to 34°C) before first contrast injection and for 3 hours after the procedure. Serum creatinine levels at baseline, 24 hours, 48 hours, and 72 to 96 hours were measured at a central core laboratory. The primary efficacy end point was development of RCN, defined as an increase in serum creatinine by ≥25{\%} from baseline. The primary safety end point was 30-day composite rate of adverse events consisting of death, myocardial infarction, dialysis, ventricular fibrillation, venous complication requiring surgery, major bleeding requiring transfusion ≥2 U, or rehospitalization. In total 128 evaluable patients (mean creatinine clearance 36.6 ml/min) were prospectively randomized at 25 medical centers. RCN developed in 18.6{\%} of normothermic patients and in 22.4{\%} of hypothermic patients (odds ratio 1.27, 95{\%} confidence interval 0.53 to 3.00, p = 0.59). The primary 30-day safety end point occurred in 37.1{\%} versus 37.9{\%} of normothermic and hypothermic patients, respectively (odds ratio 0.97, 95{\%} confidence interval 0.47 to 1.98, p = 0.93). In conclusion, in patients with CKD undergoing invasive cardiology procedures, systemic hypothermia is safe but is unlikely to prevent RCN.",
author = "Stone, {Gregg W.} and Kishor Vora and John Schindler and Claro Diaz and Tift Mann and George Dangas and Patricia Best and Cutlip, {Donald E.}",
year = "2011",
month = "9",
day = "1",
doi = "10.1016/j.amjcard.2011.04.026",
language = "English (US)",
volume = "108",
pages = "741--746",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Systemic hypothermia to prevent radiocontrast nephropathy (from the COOL-RCN randomized trial)

AU - Stone, Gregg W.

AU - Vora, Kishor

AU - Schindler, John

AU - Diaz, Claro

AU - Mann, Tift

AU - Dangas, George

AU - Best, Patricia

AU - Cutlip, Donald E.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Radiocontrast nephropathy (RCN) develops in a substantial proportion of patients with chronic kidney disease (CKD) after invasive cardiology procedures and is strongly associated with subsequent mortality and adverse outcomes. We sought to determine whether systemic hypothermia is effective in preventing RCN in patients with CKD. Patients at risk for RCN (baseline estimated creatinine clearance 20 to 50 ml/min) undergoing cardiac catheterization with iodinated contrast ≥50 ml were randomized 1:1 to hydration (control arm) versus hydration plus establishment of systemic hypothermia (33°C to 34°C) before first contrast injection and for 3 hours after the procedure. Serum creatinine levels at baseline, 24 hours, 48 hours, and 72 to 96 hours were measured at a central core laboratory. The primary efficacy end point was development of RCN, defined as an increase in serum creatinine by ≥25% from baseline. The primary safety end point was 30-day composite rate of adverse events consisting of death, myocardial infarction, dialysis, ventricular fibrillation, venous complication requiring surgery, major bleeding requiring transfusion ≥2 U, or rehospitalization. In total 128 evaluable patients (mean creatinine clearance 36.6 ml/min) were prospectively randomized at 25 medical centers. RCN developed in 18.6% of normothermic patients and in 22.4% of hypothermic patients (odds ratio 1.27, 95% confidence interval 0.53 to 3.00, p = 0.59). The primary 30-day safety end point occurred in 37.1% versus 37.9% of normothermic and hypothermic patients, respectively (odds ratio 0.97, 95% confidence interval 0.47 to 1.98, p = 0.93). In conclusion, in patients with CKD undergoing invasive cardiology procedures, systemic hypothermia is safe but is unlikely to prevent RCN.

AB - Radiocontrast nephropathy (RCN) develops in a substantial proportion of patients with chronic kidney disease (CKD) after invasive cardiology procedures and is strongly associated with subsequent mortality and adverse outcomes. We sought to determine whether systemic hypothermia is effective in preventing RCN in patients with CKD. Patients at risk for RCN (baseline estimated creatinine clearance 20 to 50 ml/min) undergoing cardiac catheterization with iodinated contrast ≥50 ml were randomized 1:1 to hydration (control arm) versus hydration plus establishment of systemic hypothermia (33°C to 34°C) before first contrast injection and for 3 hours after the procedure. Serum creatinine levels at baseline, 24 hours, 48 hours, and 72 to 96 hours were measured at a central core laboratory. The primary efficacy end point was development of RCN, defined as an increase in serum creatinine by ≥25% from baseline. The primary safety end point was 30-day composite rate of adverse events consisting of death, myocardial infarction, dialysis, ventricular fibrillation, venous complication requiring surgery, major bleeding requiring transfusion ≥2 U, or rehospitalization. In total 128 evaluable patients (mean creatinine clearance 36.6 ml/min) were prospectively randomized at 25 medical centers. RCN developed in 18.6% of normothermic patients and in 22.4% of hypothermic patients (odds ratio 1.27, 95% confidence interval 0.53 to 3.00, p = 0.59). The primary 30-day safety end point occurred in 37.1% versus 37.9% of normothermic and hypothermic patients, respectively (odds ratio 0.97, 95% confidence interval 0.47 to 1.98, p = 0.93). In conclusion, in patients with CKD undergoing invasive cardiology procedures, systemic hypothermia is safe but is unlikely to prevent RCN.

UR - http://www.scopus.com/inward/record.url?scp=80051794027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051794027&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2011.04.026

DO - 10.1016/j.amjcard.2011.04.026

M3 - Article

VL - 108

SP - 741

EP - 746

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -